Concentration-enhanced rapid detection of human chorionic gonadotropin (hCG) on a Au surface using a nanofluidic preconcentrator

Jeong Hoon Lee\textsuperscript{a} and Jongyoon Han\textsuperscript{b,\text{*}}
\textsuperscript{a} Department of Electrical Engineering, Kwangwoon University, 447-1, Wolgye, Nowon, Seoul, South Korea 139-701
\textsuperscript{b} Department of Electrical Engineering and Computer Science, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA

Abstract

Here, we report a new method of concentration-enhanced binding kinetics for a rapid immunoassay screening test on a gold surface in a poly(dimethylsiloxane) (PDMS) microfluidic chip format. The use of alkylthiolate self-assembled monolayers on gold surfaces of a PDMS-glass microchip resulted in accelerated binding kinetics of Human chorionic gonadotropin (hCG) at an electrokinetic trapping zone. We used a PBS solution (buffer concentration ~ 150 mM), not a dibasic buffer system (~10 mM), for the dynamic preconcentrating operation and the preconcentration of cy3 labeled streptavidin onto biotinylated Au surface revealed that the binding kinetics of the protein were linearly proportional to the concentration profile of the preconcentration plug. We showed rapid detection of hCG in the clinical range with a shorten assay time of 10 min. Also, we demonstrated that the amount of sample needed were detection was decreased from ~4 mL to ~25 μL in the standard serum tests. The enhanced binding kinetics between hCG Ag-Ab via preconcentration showed good feasibility for use in a rapid immunoassay screening test.

Keywords

microfluidic; nanofluidic; hCG; preconcentrator; rapid immunoassays; Nafion\textsuperscript{R} membrane

1 Introduction

To detect a low abundance of biomolecules, such as biomarkers in a complex proteomic samples, many advanced immunoassay have been developed, including SPR, nanowire sensors, nanoparticle based assays and nanomechanical sensors (Cui et al., 2001; Kukanskis et al., 1999; Lee et al., 2005). Physiological fluids such as serum contain numerous soluble proteins that spontaneously react with solid surfaces in very dynamic ways (Andrade, 1985). To minimize complex competition among over 200 proteins, several different surface chemistries on variable materials (e.g., polyurethanes, silicones, metal alloys) have been suggested. Among the materials clinically applied for the receptor surfaces of immunosensors, self-assembled monolayers (SAMs) on gold substrates are widely used and have been shown to yield the most well-ordered, homogeneous monolayers with controlled surface chemistry for DNA, protein and small molecule biosensors (Canaria et al., 2006; Dubois and Nuzzo, 1992; Kukanskis et al., 1999; Ulman, 1991). Alkylthiols SAMs on gold substrates have been...
the most widely used and has been shown to provide a very stable surface for immunosensors (Badia et al., 1997; Gong et al., 2006; Lang et al., 1999).

Previous studies have shown that the 1D planar sensor (Au surface) has a diffusion limited transport of \(-t^{1/2}\), while the 2D sensor (nanowire) and 3D sensor (nanosphere) have a diffusion limited transport of \(-t\). Consequently, the 1D sensor has a more limited response time to capture analyte molecules relative to the 2D and 3D sensors (Nair and Alam, 2006). However, alkylthiols SAMs on gold substrates is still a well-engineered surface for commercial biosensors. Moreover, one can directly utilize Au surfaces as the electric detection platform for QCM, cantilevers and nanosensors.

Our group recently developed novel nanofluidic biomolecule concentration devices that can be used to collect and trap proteins contained in a given sample into a much smaller volume, thereby significantly increasing the local concentration (Lee et al., 2007; Lee et al., 2008; Wang et al., 2005). This device can take a sample volume of 1–25 μL and continuously collect/trap any charged biomolecules, such as proteins, until a sufficient amount of the sample is collected in a very small volume (1pL to 1nL). More recently, we demonstrated that the pre-binding sensitivity could be enhanced by more than 500 fold when a charge based silicon-based nanofluidic biomolecule preconcentrator was combined with a bead-based immunoassay (Wang and Han, 2008). However, the operation of the device was only demonstrated with a 10 mM dibasic phosphate buffer solution since the 40 nm channel depth was not large enough for operation in a high buffer concentration.

In this study, we introduced a new method to increase the pre-binding concentration by combining a polymer-based nanofluidic preconcentrator with a 1D planar Au sensor, thereby increasing the local sensor area and consequently enhancing the limit of detection and shortening the assay time. Using this approach, the electrophoretic device could be operated using a Phosphate Buffered Saline solution (1× PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM, pH ~7.4).

To test the feasibility of this assay, we used Human chorionic gonadotropin (hCG) as well as the well-characterised streptavidin-biotin interaction (Weber et al., 1989). The detection and measurement of Human chorionic gonadotropin (hCG) has been generally used in early pregnancy testing. Also, hCG is an important tumor marker, since the \(\beta\) subunit of human chorionic gonadotropin is also secreted by some cancers including choriocarcinoma, germ cell tumors, hydatidiform mole formation, trophoblastic disease and testicular cancer (Cole, 1997; Kurman et al., 1977; Mock et al., 2000; Moulton et al., 2002). For example, the normal range of hCG in men is between 0–5 IU/ml and a concentration above this threshold can be used as a positive test for testicular cancer (Albers et al., 2004). In addition, the normal range of hCG in trophoblastic disease was reported to be less than 0.005 μg/mL, while serum concentrations up to 16 μg/mL were reported for one condition, persistent trophoblastic disease (vanTrommel et al., 2006). For the serum tests, a chemiluminescent or fluorimetric immunoassay was used with 2–4 mL of venous blood (McPherson, 2006).

Herein, we report that this concentration-enhanced rapid detection immunoassay was able to detect hCG in the clinical range for testicular cancer and trophoblastic disease (1 IU/mL, converted from 100 ng/mL (2.72 nM) by supplier’s data sheet) within a shorten assay time of 10 min. Also, the amount of sample needed was decreased to ~25 μL (from ~4 mL in standard serum tests).
2 Experimental

2.1 Chip design and fabrication

The PDMS preconcentrator with both surface-patterned Nafion membrane (for permselective nanochannel) and Au dot arrays (for immunoassay) on the glass substrate is shown in Fig. 1. We designed the microchannel network with the assay area (12 μm deep and 70 μm wide; in Fig. 1b) as well as the damper channel (12 μm deep, 20 μm wide and 1 mm long) to reduce the pressure drop during the dynamic preconcentration operation; in Fig. 1c). For the 1D planar Au sensor, Au dot arrays with 20 μm diameter were prepared on 4” glass wafer (Wafernet, Inc. CA). After completion of the lift-off process using standard photolithography, a 200 nm thick Au was deposited using an e-beam evaporator (Temescal VES2550) with 30 nm chrome layer for adhesion on the glass substrate (See Fig. 1b). Then, the glass wafer was coated with a 1 μm thick photoresist without baking to prevent particle contamination of the Au surface during the die-saw process. After the dicing process, the unit glass chip was thoroughly cleaned with acetone, methanol, piranha (H₂SO₄:H₂O₂=3:1) and DI water to remove dicing particles and photoresist before Nafion® printing.

Nafion® is a well-known ionomer with high ionic permselectivity due to cluster networks as well as sulfonate groups (Roche et al., 1981). Due to high ionic permselectivity, Nafion® with 190 nm thick patterned on glass functions the nanofluidic channel. Magnified images of the PDMS preconcentrator after plasma bonding between the PDMS microchannel and glass with Nafion and 1D Au dot arrays are shown in Fig. 1b. For Nafion® printing on the area between the Au dot arrays, a microflow patterning technique, which utilizes the PDMS microchannel, (reversibly bonded to glass; 120 μm deep and 200 μm wide) was applied to define the ion-selective nanobridge (Lee et al., 2008). After placing a drop of liquid Nafion® resin (1 μL) at one open reservoir on the channel, a negative pressure was applied at other open reservoir. A capillary force induced ion-selective film was formed that was 190 nm thick. The film was then cured by incubation at 95 °C for 10 minutes. The small pore size and charge density of Nafion® enabled the PDMS preconcentrator to operate when using a common assay solution (1× PBS; relatively high ionic concentration condition), which normally does not occur for Si-based preconcentrators with 40 nm deep nanochannels (Wang and Han, 2008).

2.2 Chip operation and immunoassay

To test the operation of the device in concentrating-enhanced immunoassays (See Fig. 1d), the middle channel was loaded with a protein (case 1; streptavidin in Fig. 3, case 2; hCG protein in Fig. 4) in 1× PBS; and the side channel was filled with a 1× PBS buffer solution. The device was operated in the depletion and concentration mode, as shown in Fig. 1d). After generating the depletion region by applying a potential difference (e.g., 50 V) between the microchannels (sample channel and buffer channel) through the planar ion-selective membrane (depletion mode), a potential difference across the sample channel was applied to allow the molecules to move through electroosmotic flow. Biomolecules were trapped by the depletion force due to the nanofluidic concentration polarization effect (Kim et al., 2007).

2.3 Immobilization

Fig. 2 shows the schematic steps used for the water-based hCG protein immobilization via the formation of alkylthiolate self-assembled monolayers on Au surfaces. We prepared two ethylene glycol modified alkylthilates, Tri(ethylene glycol) dodecylthiol (TEG) and Biotinylated tri(ethylene glycol) dodecylthiol (BAT), using de-ionized water with 1% ethanol (Canaria et al., 2006). Since organic solvents such as ethanol, DMSO and hexane cause swelling and consequently PDMS delamination, we purchased water-based TEG and BAT chemicals from ProChimia Surfaces and prepared stock solutions of 100 mM TEG and 100 mM BAT in ethanol. Using DI-water, we diluted the stock solution to 0.1 mM. It has been
well-known that ethylene glycol incorporation reduces the non-specific binding of protein, bacteria, and cells to Au surface (Harder et al., 1998). As a first step, we mixed a solution with a volume ratio of BAT:TEG=1:1. After filling the center microchannel for 2h to completely form the monolayers, the channel was flushed out with 1 v/o ethanol in DI-water. For the binding of streptavidin, 10 μg/mL of streptavidin was injected into the center microchannel, which was then sequentially flushed out with PBS, PBS with Tween 20 and PBS after 1 h. After binding of biotinated monoclonal 10 μg/mL anti-hCG (Fitzgerald Inc, MA) for 1h (Fig. 2d), we carried out surface blocking using a BSA (1% in PBS) solution to prevent non-specific binding. With this 1D planar sensor scheme, we assayed 100 ng/mL hCG protein (Human Chorionic Gonadotropin (HCG), Fitzgerald Inc, MA) labeled with Alexa488.

3. Results and discussion
3.1 Streptavidin-biotin interaction

The concentration-enhanced rapid immunoassay results of the streptavidin-biotin interaction were shown in Fig. 3. The biotin-streptavidin system is regarded as the strongest noncovalent biological interaction known, having a dissociation constant \(K_d\) on the order of \(4 \times 10^{-14}\) M (Green, 1990). A cy3 labeled streptavidin was used to interact with a biotinylated Au surface. The on-site preconcentration step was conducted for 10 min with 100 ng/mL of streptavidin in 1× PBS. Since it has been reported that the dissociation constant \(K_d\) is 2–3 orders larger in a low target concentration environment than the when the reaction is saturated (Mol et al., 2000), the time required for binding equilibrium to be reached will increase dramatically at lower antigen concentration (Wang and Han, 2008).

The 10 min on-site concentrated fluorescence image and linear profile was shown in Fig. 3a. The measured profile along the microchannel after the 10 min on-site preconcentration step showed that the local concentration of cy3 labeled streptavidin was drastically increased in the concentrated reaction zone, indicated by the high intensity plug in the fluorescence image and the corresponding intensity peak. After sequentially flushing out the microchannel with PBS, PBS with Tween 20, and PBS, the channel was dried completely and then the fluorescence intensity on the Au dot array was measured. Interestingly, the assay results taken from fluorescence intensity of the Au dot array showed dramatically improved binding kinetics in the preconcentration zone (Fig. 3b). The fluorescence images along the 5 points of the Au dot arrays (Fig. 3b) exactly correspond with the 10 min on-time preconcentration profile (Fig. 3a). To verify the specificity of the reaction, the assay was repeated using 1 μg/mL β-Phycoerythrin (β-PE protein; MW 240 kDa and pI~4.3; Sigma-Aldrich, MO) instead of streptavidin and no interaction was observed between the β-PE protein and biotinated Au surface (image not shown).

3.2 Immunoassay for hCG

hCG has been reported as an important tumor marker for choriocarcinoma, germ cell tumors, hydatidiform mole formation, and testicular cancer (Cole, 1997; Kurman et al., 1977; Mock et al., 2000; Moulton et al., 2002); thus, there is a need to develop novel methods to detect hCg. The dissociation constant, \(K_d\), of the hCG antibody was reported to be \(6.2 \times 10^{-9}\) M based on the supplier’s data sheet (http://www.fitzgerald-fii.com/uploadDocs/dataSheets/3463.pdf). When the target concentration was significantly below the \(K_d\) of the antibody, the interaction of the low-concentration target and the antibody is usually diffusion-limited (de Mol et al., 2000). As a result, a long reaction (incubation) time is typically required from several hours to overnight when using low concentration immunoassays (Sandro Cesaro-Tadic et al., 2004).
To verify the specificity of the interaction, the preconcentration operation was conducted with the β-PE protein in 1× PBS, 1 mg/mL of the BSA background protein and the biotinylated monoclonal anti-hcG immobilized Au dot array as shown in Fig. 4a. Fluorescence images were taken 10 min after the on-site preconcentrating operation and demonstrated that the operation was stable in 1× PBS solution. After washing the microchannel with PBS, PBS with Tween 20, and PBS, we confirmed that no non-specific binding events between immobilized anti-hcG and β-PE protein occurred (image not shown). To detect the specific binding event between anti-hcG and the hcG protein, the same 10 min on-site preconcentration step was conducted with 100 ng/mL of the hcG protein in a 1× PBS, 1 mg/mL of the BSA background protein and the biotinylated monoclonal anti-hcG immobilized Au dot array. From the supplier’s data sheet, 100 ng/mL of the hcG protein should be converted to 1 IU/mL. Since the hcG concentration was (2.72 nM, 100 ng/mL) was below the K_d value of the hcG antibody (6.2 nM), the Ag-Ab interaction was diffusion-limited, consequently, the reaction time could be quite long and last up to hours. Fig. 4b shows the fluorescence image and intensity profile of electrokinetic trapping (taken after 10 min preconcentration). In addition, Fig. 4c showed the fluorescence image and intensity profile of hcG Ab-Ag interaction after the washing and drying step with a N2 gun. The washing step was carried out with PBS, PBS with Tween 20, and PBS.

As observed for the biotin-streptavidin system, the Au dot arrays of hcG and anti-hcG binding event in the electrokinetic trapping zone displayed a significantly enhanced signal. The location of the preconcentration plug (4 bright dots in Fig. 4b) exactly corresponded with the 10 min on-time preconcentration profile (Fig. 4a). The fact that no significant increase in the fluorescence signal after 60 min of interaction between hcG and anti-hcG without the preconcentration step in the microchannel at same concentration (100 ng/mL hcG; data not shown) was observed demonstrates the distinct advantages of the on-site preconcentration device.

The enhanced sensitivity (Fig. 4c) as well as the preconcentration factor (Fig. 4b) was quantified using the reference fluorescence signal (50 μg/mL hcG; 500-fold higher concentration of assayed one). 50 μg/mL hcG was placed into the microchannel and the fluorescence intensity was measured without a preconcentration step after a 10 min interaction (linear dot profile in the graph of Fig. 4b). As shown in Fig. 4b, the sample concentration increased by at least 500-fold in 10 min. After the washing and dry step, we measured the line profile from the fluorescent signal. The line profile of the fluorescence signal indicated that the sensitivity of detecting bound protein on the Au surface was enhanced by 500-fold. In addition, we shorten the assay time to 10 min and decreased the amount of sample needed to ~25 μL (from ~4 mL in standard serum tests). This binding kinetics follows the Langmuir isotherm $\theta = 1 - e^{-c(x)k}t$, where $\theta$ is the fraction of surface coverage of hcG, $c(x)$ is the protein concentration at position $x$, $k$ is the reaction rate of the protein with the surface, and $t$ is time. Evidently, one can expect that an increase in the local concentration at a constant binding time results in an increase in the fraction of surface coverage.

4 Conclusions

In this study, we developed a rapid pre-screen immunoassay method via concentration-enhanced binding kinetics. For the rapid immunoassay, we combined a simple disposable microfluidic chip format with alkylthiolate self-assembled monolayers on a 1D gold surface. By exploiting the high ionic permselectivity of Nafion®, which reduces the cluster network and the effective channel size and contains sulfonate groups, we demonstrated that this novel device could be stably operated in the high ionic concentrations of a PBS solution, and not in a dibasic buffer system (~10 mM). In addition, the assay time for the detection of HCG in the clinical ranges for testicular cancer and trophoblastic disease was decreased to 10 min. Also, the amount of sample needed was decreased from ~4 mL to ~25 μL in standard serum tests.
The enhanced binding kinetics between hCG Ag-Ab via preconcentration demonstrated that this technique holds great promise as a rapid immunoassay screening method for detection of small concentrations. Due to its sensitivity, we expect that it will be used as a pre-binding signal enhancement tool to detect low-abundance proteins and peptides. Furthermore, the PDMS microfluidic immunoassay format would allow for direct integration with many different biosensors using 1D Au surfaces that utilized post-binding amplification (i.e. QCM, cantilever and nanosensor).

**Acknowledgments**

This work was supported by NIH (CA119402). J. H. Lee is partially supported by the Research Grant of Kwangwoon University in 2009.

**References**


Mol, NJd; Plomp, E.; Fischer, MJE.; Ruijtenbeek, R. Kinetic analysis of the mass transport limited interaction between the tyrosine kinase lck SH2 domain and a phosphorylated peptide studied by a new cuvette-based surface plasmon resonance. Anal Biochem 2000;279:61–70. [PubMed: 10683231]


Cesaro-Tadic, Sandro; Dernick, Gregor; Juncker, David; Buurman, Gerrit; Kropshofer, Harald; Michel, Bruno; Fattinger, Christof; Delamarche, E. High-sensitivity miniaturized immunoassays for tumor necrosis factor using microfluidic systems. Lab Chip 2004;4:563–569. [PubMed: 15570366]


Fig. 1.
(a) Schematic of the PDMS preconcentrator with the surface-patterned Nafion membrane on the glass substrate and its operation. (b) Au dot arrays (diameter =20 μm) on the glass slide for the immunoassay application. The middle channel is loaded with a hcG protein (in 1× PBS) and the side channel is filled with a 1× PBS buffer solution. (c) Damper design for reducing the pressure difference between the two reservoirs. (d) For preconcentration, a potential difference was applied across the middle and the side channel in combination with an electrokinetic flow. All the microchannels were 12 μm deep and 70 μm wide.
Fig. 2.
Schematics of anti-hcG immobilization via the formation of alkylthiolate self-assembled monolayers on the Au surface. (a) Formation of Tri(ethylene glycol) dodecylthiol (TEG) and Biotinylated tri(ethylene glycol) dodecylthiol (BAT) on the Au surface. (b) binding of streptavidin. (c) binding of biotinated monoclonal anti-hcG. (d) surface blocking using BSA (1% in PBS) for preventing non-specific binding. (e) Immunoassay using hcG protein labeled with Alexa488.
Fig. 3.
(a) Preconcentration step using cy3 labeled streptavidin binding to a biotinylated Au surface (after 10 min on-site preconcentration with 100 ng/mL streptavidin in 1× PBS) (b) Fluorescence image after washing the microchannel with the sequential injection of PBS, PBST (PBS with Tween20) and PBS. Fluorescence intensity of each Au dot indicates dramatically improved binding kinetics in the preconcentration zone.
Fig. 4.
(a) Stable operation of the Preconcentration step (after 10 min, 1 µg/mL bBE in 1 PBS; with 1mg/mL BSA background protein; V_1=50V and V_2=25V, V_3=V_4=GND in Fig. 1). No non-specific binding events between immobilized anti-hcG and bPE proteins were observed (image not shown). Magnified fluorescence image and intensity profile of (b) preconcentration of hcG protein (taken after 10 min preconcentration, 100 ng/mL hcG antigen in 1× PBS; with 1mg/mL BSA background protein) and (c) fluorescence image and intensity profile after the washing and dry step of device b. These images demonstrate the enhanced binding kinetics between hcG Ag-Ab via preconcentration. From the reference intensity (hcG 50 µg/mL; dot line), a 500 fold increase in the sensitivity of the assay was observed.